Global Diabetic Retinopathy Market

Global Diabetic Retinopathy Market Analysis

The diabetic retinopathy market reached USD 10.08 million in 2025 and is projected to expand to USD 13.71 million by 2030, reflecting a 6.35% CAGR. Growth stems from the rising global diabetes burden, rapid uptake of AI-enabled screening, and broader therapeutic choices that now include sustained-release biologics and pipeline gene therapies. Aging populations amplify demand, with nearly 10 million patients in the United States and more than 100 million worldwide living with some form of diabetic retinopathy. North America retains leadership on the strength of advanced health systems, while Asia-Pacific shows the fastest gains as tele-ophthalmology programs scale across large diabetic populations. Competitive intensity rose sharply in 2024 when five aflibercept biosimilars entered the United States, triggering price competition and widening patient access.

Global Diabetic Retinopathy Market Trends and Insights

Rising Global Diabetes Prevalence & Earlier Screening

International Federation of Diabetes data foresee 12% of the world’s adults living with diabetes by 2045, enlarging the treatable pool for the diabetic retinopathy market ^{[1]International Diabetes Federation, “IDF Diabetes Atlas,” idf.org}. Meta-analyses confirm disease rates above 22% in multiple screening programs, underlining a consistent burden across regions. AI tools that deliver 92-93% sensitivity now detect micro-aneurysms at routine primary-care visits, shifting diagnosis to earlier, more treatable stages. Chile’s national tele-ophthalmology network cut specialist referrals to 15% while preserving coverage, showing scalable early detection in lower-resource settings.

Aging Population Increasing Vision-Threatening Cases

Patients with more than 10 years of diabetes carry 4.36-fold higher odds of retinopathy, and most are over 60 years old. China reports prevalence between 24.7% and 43.1%, highlighting the aging-duration nexus in the region. Female patients have shown bigger increases in blindness, suggesting the need for gender-specific care strategies. Vitrectomy demand mirrors these trends, expanding 8.14% annually as elderly patients present with complex proliferative disease.

Expanding Indications & Reimbursement for Long-Acting Anti-VEGF Biologics

Five U.S. aflibercept biosimilars secured FDA approval in 2024, creating downward price pressure and broader payer coverage. Genentech’s Susvimo received clearance for continuous delivery with two refills a year, and Regeneron’s Eylea HD is under priority review for longer dosing intervals, both directly addressing the 46% break-off rate seen in diabetic macular edema.

AI-Enabled Retinal Screening Adoption in Primary-Care Clinics

AEYE Health won FDA clearance for the first fully autonomous AI algorithm that needs only one image per eye, achieving 99% imageability and over 92% sensitivity. Less than 5% of U.S. diabetics accessed AI screening between 2019-2023, leaving substantial headroom for expansion. India’s plan to scan 1 billion eyes over 10 years illustrates the scalability of AI combined with low-cost handheld cameras. Real-world Czech data show AI outperforms general ophthalmologists in sensitivity while raising follow-up adherence by 89%.

Shortage of Retinal Specialists in Emerging Markets

The United States is projected to face a 12% fall in ophthalmologist supply versus a 24% rise in demand by 2035, and rural counties may meet only 26-29% of their staffing need ^{[2]American Academy of Ophthalmology, “Ophthalmologist Workforce Projections,” aaojournal.org} . Asia-Pacific shows even sharper gaps as diabetic prevalence climbs faster than specialist training, prompting governments to fund telemedicine hubs and AI triage to extend reach. Arkansas illustrated scalable coverage using statewide teleretinal screening linked to urban retina centers, an approach now copied in Latin America and South Asia.

High Treatment Burden & Poor Adherence to Injection Regimens

Real-world audits find 46% of diabetic macular edema patients discontinue anti-VEGF therapy at least once, twice the dropout seen in age-related macular degeneration. Monthly office visits, cost, and co-morbidities all undermine adherence. Continuous delivery reservoirs such as Susvimo, extended-interval Eylea HD, and one-time RGX-314 gene therapy aim to relieve this burden and are already showing superior durability in trials.

Segment Analysis

By Type: Non-Proliferative Dominance Drives Early Intervention

Non-proliferative disease accounted for 63.25% diabetic retinopathy market share in 2024, underscoring the impact of screening that now captures pathology earlier. AI systems detecting subtle micro-aneurysms push more patients into preventive care pathways rather than late-stage surgery. Proliferative cases, although smaller, will rise at 7.38% CAGR as aging and disease duration fuel advanced pathology, expanding demand for surgery and regenerative therapies.

Clinical management differs sharply. Non-proliferative patients benefit from systemic agents such as fenofibrate, which cut progression by 27% in trials. Proliferative disease increasingly involves vitrectomy, the fastest-growing modality at 8.14% CAGR. Early gene therapy data show 2-step DRSS improvement in 20% of treated non-proliferative patients, suggesting future disease-stage-specific regimens. The diabetic retinopathy market size for proliferative interventions is projected to outpace overall growth despite the segment’s current smaller base.

By Management Approach: Anti-VEGF Leadership Faces Sustained-Release Disruption

Anti-VEGF drugs held 56.25% of the diabetic retinopathy market size in 2024 on entrenched physician familiarity and wide-ranging guideline support ^{[3]Food and Drug Administration, “FDA Approvals of Aflibercept Biosimilars,” fda.gov} . The segment is pivoting toward durability. Susvimo’s reservoir requires two refills a year, and Vabysmo offers dual-pathway inhibition, both carving share from monthly injectables.

Vitrectomy volume will expand fastest at 8.14% CAGR as surgeons treat complex tractional detachments in proliferative disease, with Japan reporting 97.3% single-surgery success. Steroid implants fill a niche for inflammation-driven edema, lowering injection frequency from 4.7 to 1.4 annually. Laser photocoagulation remains useful in combination protocols; meta-analyses show ranibizumab plus laser yields better vision than monotherapy in select cases. Overall, the diabetic retinopathy market continues to shift from frequent injections toward longer-lasting biologics, surgery, and, eventually, one-time gene therapy.

By End-User: Hospital Dominance Shifts Toward Specialized Clinic Growth

Hospitals commanded 51.40% share of the diabetic retinopathy market in 2024 thanks to operating-room access for vitrectomy and multi-disciplinary management of co-morbidities. Procedure-heavy proliferative cases solidify hospital strength, yet cost pressures encourage migration to outpatient settings.

Ophthalmology clinics will grow at 7.75% CAGR, boosted by consolidation that creates nationwide retinal care networks, such as Cencora’s USD 5.1 billion purchase of Retina Consultants of America. Ambulatory surgical centers gain momentum as sustained-release devices like Susvimo can be implanted in minor-procedure suites. AI screening now launches in primary-care offices, routing positive cases to clinic-based retina specialists, broadening the referral funnel. These shifts produce a more distributed care model while maintaining hospital dominance for the most complex surgeries.

Geography Analysis

North America captured 43.35% of diabetic retinopathy market share in 2024, supported by early adoption of FDA-cleared AI devices, fast biosimilar uptake, and generous payer coverage. The region hosts 71.15% of global diabetic eye research publications from 2012-2021, reinforcing its innovation leadership. A looming 30% shortfall in ophthalmologist supply by 2035 tempers growth, particularly in rural areas, and fuels demand for tele-retina solutions.

Asia-Pacific is expected to grow at 8.25% CAGR through 2030, the highest of all regions, propelled by diabetes incidence and large population bases. China’s diabetic retinopathy prevalence up to 43.1% among diabetics underscores the region’s unmet need. India’s plan to screen 1 billion eyes with AI-enabled handheld cameras highlights large-scale digital health adoption. Government reimbursement expansion and rising medical tourism further spur growth.

Europe demonstrates steady growth on the strength of robust universal health systems and swift biosimilar integration. Latin America leverages tele-ophthalmology, exemplified by Chile’s network that detects retinopathy in 22% of screened diabetics while cutting unnecessary referrals. The Middle East and Africa remain nascent but attractive due to high diabetes prevalence in Gulf states and incremental investment in specialty care infrastructure.

Competitive Landscape

The diabetic retinopathy market shows moderate consolidation. Top participants include Genentech (Susvimo, ranibizumab biosimilars), Regeneron (Eylea, Eylea HD), Roche (Vabysmo), Novartis (Beovu), Bayer, AbbVie/REGENXBIO (RGX-314), and emerging biosimilar developers. Five aflibercept biosimilars approved in 2024—Yesafili, Opuviz, Enzeevu, Pavblu, and one unbranded—apply price pressure yet widen access.

Differentiation now centers on durability. Susvimo’s port-delivery system and Eylea HD’s extended intervals are setting new treatment expectations. Roche’s Vabysmo leveraged dual inhibition to reach 847 million Swiss francs in Q1 2024 sales, proving rapid physician adoption.

M&A and partnerships reshape service delivery. Cencora’s acquisition of Retina Consultants of America builds a national clinic platform, while AEYE Health pairs with Optomed to commercialize AI-enabled handheld cameras. Gene therapy represents the next competitive frontier; RGX-314’s Phase 3 program aims to establish a one-time treatment that could shift future share dynamics.